Abstract
Asbestos is a well-known toxin and lung carcinogen. Epidemiologic studies have established tobacco smoke and asbestos exposures synergistically interact to enhance lung cancer risk. The biologic mechanism responsible for this interaction has been the subject of considerable debate. Studies have suggested that asbestos may act as a carcinogen by generating free radical and reactive oxygen species, by inducing tissue injury and subsequent cellular growth, via large-scale chromosome loss and by enhancing delivery of tobacco carcinogens to the respiratory epithelium. Recent molecular epidemiologic approaches further suggest that asbestos enhances the mutagenicity of tobacco carcinogens and that it acts, at least in part, independent of the tissue damage responsible for fibrosis.
Similar content being viewed by others
Introduction
Asbestos is a natural occurring fibrous hydrated magnesium silicate mineral that has multiple commercial uses as a result of its indestructible character. The majority of asbestos used in the United States has been serpentine chrysotile asbestos, while amphibole asbestos (notably amosite and crocidolite) has been mined primarily in South Africa, India, Bolivia and Australia and seen less (albeit significant) use world-wide (Wilt et al., 1998). Asbestos has been used primarily in products that require heat resistance (e.g. insulation). Its use in the United States peaked during and after World War II as a result of its extensive use in shipbuilding and commercial construction.
Exposure in the workplace has been significant for asbestos miners and millers, as well as for those exposed during secondary manufacturing uses (Rom, 1998). Construction workers (particularly asbestos insulators or ‘laggers’) have had historically very heavy inhalation exposures as a result of mixing and spraying asbestos on the job. In the United States asbestos use diminished when fiberglass insulation was introduced (circa 1965) and declined further after OSHA regulated workplace asbestos exposure in 1972. However, the use of asbestos has continued to increase in the developing world (Huncharek, 1993). One example of the dynamic pattern of worldwide use of asbestos is illustrated by the recent World Trade Organization decision upholding France's ban on the import and use of chrysotile. This decision is likely to increase the pressure for producers to target sales and use of asbestos to the developing world (Kazan-Allen, 2001). Hence, patterns of occupational exposure to asbestos are complex, dynamic and quite difficult to estimate in both the United States and the developing world.
Asbestos has long been known as a potent occupational toxin and lung carcinogen (Blot and Fraumeni, 1996; Rom, 1998; Russi and Cone, 1994). While tobacco smoke is clearly the single greatest risk factor for lung cancer, significantly increased risks for lung cancer have been observed in both non-smokers and smokers exposed to asbestos (Blot and Fraumeni, 1996; Selikoff et al., 1968). A large body of epidemiologic evidence has demonstrated that smoking and asbestos exposure, occurring together, have a more than additive action in causing lung cancer (Selikoff et al., 1968; Vainio and Boffetta, 1994). The relationship between these exposures has been termed ‘synergistic,’ meaning that they act in a multiplicative fashion (Rothman, 1976). Quantification of the magnitude of these risks is problematic as they clearly are dose and time dependent, but in epidemiologic studies of workers with significant exposure to both asbestos and tobacco smoke, asbestos exposure alone is associated with an approximate fivefold increase in lung cancer risk (above unexposed workers), smoking alone with about a 10-fold risk and in workers with both exposures risk has been estimated at about 50-fold above that for the unexposed (Selikoff et al., 1968). Measures of this interaction across studies have shown considerable variation, but studies of the highest exposures point to an interaction that is multiplicative (Vainio and Boffetta, 1994). The epidemiologic data addressing the lung cancer risk from asbestos exposure and the accepted interaction with tobacco smoke exposure have been intensively analysed. The interaction appears to hold for all histologic subtypes (Vainio and Boffetta, 1994). Further, although fraught with uncertainty, the dose extrapolations are also consistent with a linear dose-response for the interactive risk.
Since asbestos is well known to cause interstitial fibrosis, it has been suggested that the fibrosis is central to the lung cancer process (Browne, 1986; Weiss, 1988b). This question has proven particularly controversial and presents a vexing epidemiologic problem; both interstitial fibrosis and lung cancer are dose-related and disentangling their various independent contributions to disease requires extremely large study groups with documented and variable exposure histories (Blot and Fraumeni, 1996; Craighead and Mossman, 1982; Mossman et al., 1983). While large studies have been conducted, there may not be adequate data resources to answer this question with the epidemiologic approach. The idea that asbestos-induced lung cancers follow an etiologic pathway that includes fibrosis flows from the observations that asbestos fiber deposition occurs primarily in the lower lobes of the lung and can be followed by induction of asbestosis and the formation of a ‘scar’ carcinoma (adenocarcinoma). Many studies have supported this general mechanism, reporting an increased proportion of lower lobe tumors among asbestos exposed populations (Craighead and Mossman, 1982; Jacob and Anspach, 1965; Kannerstein and Churg, 1972; Karjalainen, 1993; Soutar et al., 1974; Talcott and Antman, 1988; Weiss, 1988a; Whitwell et al., 1974), as well as an increased proportion of adenocarcinomas in asbestos exposed lung cancer patients (Auerbach et al., 1979; Browne, 1986; Hourihane and Mccaughey, 1966; Husgafvel-Pursiainen et al., 1999; Johansson and Albin, 1992; Karjalainen, 1994; Mollo et al., 1995; Raffin et al., 1993; Talcott and Albin, 1988; Whitwell et al., 1974). However, these associations have not been reported by all studies (Auerbach et al., 1984; Brodkin et al., 1997; Churg, 1985; deklerk et al., 1996; Hillerdal et al., 1983; Huuskonen, 1978; Kannerstein and Churg, 1972; Lee et al., 1998; Vainio and Boffetta, 1994), and as the proportion of adenocarcinoma and lower lobe tumors have steadily increased among non-asbestos exposed populations (i.e. women and former smokers) the implications of these patterns have become less clear.
The epidemiologic data also have little to say about the biologic basis of either the carcinogenic effect of asbestos alone or the combined effect of asbestos and tobacco smoke exposure. In vitro studies have shown asbestos to be cytotoxic, clastogenic and, although it is not an Ames assay mutagen, asbestos is mutagenic in systems that detect large deletions of DNA (Both et al., 1994; Hei et al., 1992; Jaurand et al., 1986; Okayasu et al., 1999). Asbestos fibers can induce chromosomal aberrations and large deletion events by interfering with mitotic machinery resulting in the abnormal segregation of chromosomes (Ault et al., 1995; Cole et al., 1991; Dopp et al., 1995; Hesterberg and Barrett, 1985; Jensen et al., 1996; Kodama et al., 1993; Palekar et al., 1987; Sincock and Seabright, 1975; Valerio et al., 1983; Yegles et al., 1993). Workers exposed to asbestos have been reported to have increased levels of sister chromatid exchanges (Fatma et al., 1991; Rom et al., 1983), as do non-smokers with high environmental asbestos exposures (Donmez et al., 1996). In addition, exposed workers have an elevated incidence of DNA double-strand breaks in lymphocyte DNA (Marczynski et al., 1994).
The DNA damage caused by asbestos may be related, at least in part, to the generation of oxidative damage (Maples and Johnson, 1992; Schapira et al., 1994; Weitzman and Graceffa, 1984; Kamp et al., 1992). This mechanism is attractive as it might also be related to the generation of tissue inflammation and cell death related to the pulmonary fibrosis commonly associated with asbestos exposure. There are many lines of evidence that support a mechanistic role for asbestos mediated reactive oxygen species (ROS) in lung cancer (Kamp et al., 1992). Antioxidants quench fiber-induced mutagenesis (Dong et al., 1994; Goodglick and Kane, 1986; Hei et al., 1995; Korkina et al., 1992; Mossman et al., 1986). Asbestos fibers promote the formation of hydroxyl radicals (Maples and Johnson, 1992; Schapira et al., 1994; Weitzman and Graceffa, 1984) a process catalyzed by the presence of fiber-bound metals (Fubini and Mollo, 1995; Lund and Aust, 1992; Park and Aust, 1998; Zalma et al., 1987), and asbestos exposure results in elevated 8-OHdG DNA adducts, a biomarker of ROS exposure, both in vitro and in vivo (Adachi et al., 1992, 1994; Chao et al., 1996; Chen et al., 1996; Fung et al., 1997; Marczynski et al., 2000; Murata-Kamiya et al., 1997; Nejjari et al., 1993; Takahashi et al., 1997; Takeuchi and Morimoto, 1994; Xu et al., 1999)
Smoking also induces cell proliferation, inflammation, and the production of ROS. In fact, very early radiographic changes that mimic an early fibrotic pattern are associated with smoking (Lilis et al., 1991). The combination of smoking and asbestos exposure has been shown to increase the occurrence of both lung fibrosis (Lilis et al., 1991) and cell proliferation (Sekhon et al., 1995). In addition, cigarette smoking may enhance the lifetime accumulation of asbestos fibers (Churg and Stevens, 1995). Increased cell turnover related to the toxic effects of inhaled tobacco smoke and asbestos almost certainly increases the occurrence of somatic alterations in newly dividing cells. Thus, the observations of asbestos and tobacco smoking enhancing airway changes as well as inflammation and fibrosis may, in some part, help to explain the synergy between asbestos exposure and cigarette smoking for lung cancer risk.
Possibly the best mechanistic explanation for the multiplicative effects of asbestos and cigarette smoking involves a model where asbestos fibers serve as a vehicle to deliver concentrated doses of tobacco carcinogens to the nucleus of the target cell (Brown et al., 1983; Gerde and Scholander, 1988; Lakowicz et al., 1980; Menrad et al., 1986). Surfactant phospholipids coating the lung epithelium adhere to the asbestos fibers creating a lipid bilayer where hydrophobic carcinogens such as polycyclic aromatic hydrocarbons (PAH's) may solubilize (Gerde and Scholander, 1988, 1989). This would result in a concentrated smoking carcinogen exposure at the lung epithelium. If asbestos acts in this fashion, the biologic effects would be indistinguishable from that of cigarette smoke alone except that the dose and dose-rate of carcinogen exposure would be significantly enhanced above non-asbestos exposed individuals. However, it remains unclear whether the synergistic effects of combined exposure depend on the physical interaction between asbestos and tobacco smoke, whether these multiplicative effects reflect saturation of repair mechanisms for ROS, or whether one exposure applies selective pressure for clones initiated by the other exposure (classic tumor promotion).
Epidemiologic studies using a case series approach to study somatic alterations in primary human lung tumors from asbestos-exposed and unexposed patients may be critically useful in delineating the underlying mechanism(s) of the asbestos/smoking synergy. Studies using this approach have demonstrated that asbestos exposure is associated with particular types of somatic gene alterations. Nelson et al. (1998) reported asbestos exposure and smoking to be associated with deletion of the FHIT gene in lung cancer. Reduced FHIT protein expression and increased LOH observed in the lung tumors of asbestos exposed patients support these findings (Pylkkanen et al., 2002). Asbestos is a well-known clastogen and the enhanced large-scale allele loss observed in these studies is consistent with asbestos acting in this fashion.
Husgafvel-Pursianinen et al. (1993) first suggested that asbestos exposure enhanced the association of tobacco smoke exposure and the occurrence of k-ras mutations in adenocarcinoma. Mutations at k-ras are primarily G to T transversions at codon 12, and this type of alteration (transversion mutations) has been associated with the action of polyaromatic hydrocarbons and very likely represents the action of tobacco carcinogens at the cellular level (Denissenko et al., 1996). Additional studies have confirmed this observation of asbestos enhancement of smoking-related mutations (Husgafvel-Pursiainen et al., 1995; Nelson et al., 1999; Wang et al., 1995), however, significant potential confounding by histology may obscure the ability to detect associations (Husgafvel-Pursiainen et al., 1999). In addition, it has been shown that these types of transversion mutations at k-ras occur in asbestos exposed individuals without evidence of fibrotic alterations (Nelson et al., 1999). That is, this molecular evidence implies that asbestos exposure is related to lung cancer in the absence of asbestosis. Finally, p53 mutations and aberrant protein expression in lung cancer have been associated with asbestos exposure (Husgafvel-Pursiainen et al., 1995; Liu et al., 1998; Nuorva et al., 1994; Wang et al., 1995). The prevalence of G:C to T:A transversion mutations at p53 may be enhanced by asbestos exposure in a fashion related to combined asbestos and tobacco carcinogen dose (Wang et al., 1995). This adds further molecular evidence to the hypothesis that asbestos fibers act by enhancing the delivery of polyaromatic carcinogens to the lung.
Hence, the precise mechanisms responsible for the action of asbestos as a lung carcinogen either alone or in combination with tobacco smoke remain the subject of considerable scrutiny. Studies using a molecular epidemiologic approach are suggesting that the combined exposure results in more mutations that are of the particular type produced by tobacco carcinogens than otherwise occur in the absence of asbestos exposure. In addition, evidence now suggests that the molecular changes may be independent of fibrosis and implies that the pathways for fibrosis and lung cancer are, at least in some critical ways, distinct.
Expansion of the molecular epidemiologic approach may improve our understanding of the asbestos-smoking interaction. For example, little work has been done to date examining other classes of somatic changes that are associated with carcinogen exposure. Several studies have investigated the association of smoking and p16 gene promoter methylation in lung cancer (Kim et al., 2001; Sanchez-Cespedes et al., 2001; Zochbauer-Muller et al., 2001). However, little research has asked if asbestos exposure might enhance the magnitude of this effect (Kim et al., 2001).
It will be difficult to determine with certainty that asbestos is associated with a unique spectrum of genetic alterations. These studies will be limited in their power to attribute changes to asbestos exposure alone as lung cancer in non-smoking asbestos-exposed individuals is (fortunately) becoming more rare in the United States (as exposure in the workplace diminishes). Determining the independent and joint effects of asbestos and tobacco in lung cancer will require investigating large numbers of non-smoking asbestos exposed individuals. It may be useful to examine the types of somatic changes that are found in mesothelioma, a tumor attributable almost solely to asbestos exposure. These studies suggest that there is overlap in the spectrum of genes inactivated in this disease (e.g. p16 inactivation), but the frequency and type of alterations are distinct from lung cancer (Hirao et al., 2002). In addition, all studies of the molecular epidemiology of lung cancer will be limited by their ability to estimate asbestos exposure. At a minimum these studies should include careful occupational histories, noting patient occupation over time in a fashion that might allow for some estimation of duration and intensity of asbestos exposure. Finally, the disturbing experience of the United States with respect to tobacco smoking and the use of asbestos is in the process of being repeated in the developing world. Prevention of this obvious public health emergency must be a priority for all health professionals. However, as this clearly predictable epidemic of lung cancer unfolds, studies of the workers exposed to asbestos are possible and could provide additional information on the mechanism of action of asbestos and tobacco carcinogens in the genesis of lung cancer.
References
Adachi S, Kawamura K, Yoshida S, Takemoto K . 1992 Int. Arch. Occup. Environ. Health 63: 553–557
Adachi S, Yoshida S, Kawamura K, Takahashi M . 1994 Carcinogenesis 15: 753–758
Auerbach O, Garfinkel L, Parks VR . 1979 Cancer 43: 636–672
Auerbach O, Garfinkel L, Parks VR, Conston AS, Galdi VA, Joubert L . 1984 Cancer 54: 3017–3021
Ault J, Cole RW, Jensen CG, Jensen LCW, Bachert LA, Rieder CL . 1995 Cancer Res. 55: 792–798
Blot W, Fraumeni JF . 1996 Cancer Epidemiology and Prevention Schottenfeld D and Fraumeni JF (eds) New York: Oxford University Press pp. 637–665
Both K, Henderson DW, Turner DR . 1994 Int. J. Cancer 59: 538–542
Brodkin C, McCullough M, Stover B, Balmes J, Hammar S, Omenn GS, Checkoway H, Barnhart S . 1997 Am. J. Ind. Med. 32: 582–591
Brown R, Fleming GS, Knight AI . 1983 Environ. Health Perspect. 51: 315–318
Browne K . 1986 Br. J. Ind. Med. 43: 145–149
Chao C, Park SH, Aust AE . 1996 Arch. Biochem. Biophys. 326: 152–157
Chen Q, Marsh J, Ames B, Mossman B . 1996 Carcinogenesis 17: 2525–2527
Churg A . 1985 JAMA 253: 2984–2985
Churg A, Stevens B . 1995 Am. J. Respir. Crit. Care Med. 151: 1409–1413
Cole R, Ault JG, Hayden JH, Rieder CL . 1991 Cancer Res. 51: 4942–4947
Craighead J, Mossman BT . 1982 N. Engl. J. Med. 306: 1446–1455
deKlerk N, Musk AW, Eccles JL, Hansen J, Hobbs MST . 1996 Occup. Environ. Med. 53: 157–159
Denissenko M, Pao A, Tang MS, Pfeifer GP . 1996 Science 274: 430–432
Dong H, Buard A, Renier A, Levy F, Saint-Etienne L, Jaurand MC . 1994 Carcinogenesis 15: 1251–1255
Donmez H, Ozkul Y, Ucak R . 1996 Mutation Res. 361: 129–132
Dopp E, Saedler J, Stopper H, Weiss DG, Schiffmann D . 1995 Environ. Health Perspect. 103: 268–271
Fatma N, Jain AK, Rahman Q . 1991 Br. J. Ind. Med. 48: 103–105
Fubini B, Mollo L . 1995 Toxicol. Lett. 82: 951–960
Fung H, Kow YW, Van Houten B, Mossman BT . 1997 Carcinogenesis 18: 825–832
Gerde P, Scholander P . 1988 Br. J. Ind. Med. 45: 682–688
Gerde P, Scholander P . 1989 Env. Health Perspect. 79: 249–258
Goodglick L, Kane AB . 1986 Cancer Res. 46: 5558–5566
Hei T, Piao CQ, He ZY, Vannais D, Walsren CA . 1992 Cancer Res. 52: 6305–6309
Hei T, He ZY, Suzuki K . 1995 Carcinogenesis 16: 1573–1578
Hesterberg T, Barrett JC . 1985 Carcinogenesis 6: 473–475
Hillerdal G, Karlen E, Aberg T . 1983 Br. J. Ind. Med. 40: 380–383
Hirao T, Bueno R, Chen C-J, Gorden GJ, Helig E, Kelsey KT . 2002 Carcinogenesis, in press
Hourihane D, McCaughey WTE . 1966 Postgrad. Med. J. 42: 613–622
Huncharek M . 1993 J. Pub. Health Policy 14: 51–65
Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, Antilla S, Karjalainen A, Partanen T, Taikina-Aho O, Heikkila L, Vainio H . 1993 Int. J. Cancer 53: 250–256
Husgafvel-Pursiainen K, Ridanpaa M, Anttila S, Vainio H . 1995 J. Occ. Env. Med. 37: 69–76
Husgafvel-Pursiainen K, Karjalainen A, Kannio A, Anttila S, Partanen T, Ojajarvi A, Vainio H . 1999 Am. J. Respir. Cell Mol. Biol. 20: 667–674
Huuskonen M . 1978 Scand. J. Work Environ. Health 4: 265–274
Jacob G, Anspach M . 1965 Ann. NY Acad. Sci. 132: 536–538
Jaurand M, Kheuang L, Magne L, Bignon J . 1986 Mutat. Res. 169: 141–148
Jensen C, Jensen LC, Rieder CL, Cole RW, Ault JG . 1996 Carcinogenesis 17: 2013–2021
Johansson L, Albin M . 1992 Br. J. Ind. Med. 49: 626–630
Kamp D, Graceffa P, Pryor WA, Weitzman SA . 1992 Free Radic. Biol. Med. 12: 293–315
Kannerstein M, Churg J . 1972 Cancer 30: 14–21
Karjalainen A, Anttila S, Heikkila L, Kyyronen P, Vaino H . 1993 Scand. J. Work Environ. 19: 102–107
Karjalainen A, Anttila S, Vanhala E, Vaino H . 1994 Scand. J. Work Environ. Health 20: 243–250
Kazan-Allen L . 2001 Int. J. Health Services 31: 481–493
Kim D, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, Mark EJ, Kelsey KT . 2001 Cancer Res. 61: 3419–3424
Kodama Y, Boreiko CJ, Maness SC, Hesterberg TW . 1993 Carcinogenesis 14: 691–697
Korkina L, Durnev AD, Suslova TB, Chersmisina ZP, Daugel-Dauge NO, Afanas'ev IB . 1992 Mutat. Res. 265: 245–253
Lakowicz J, Bevan DR, Riemer SC . 1980 Biochem. Biophys. Acta 629: 243–258
Lee B, Wain JC, Kelsey KT, Wiencke JK, Christiani DC . 1998 Am. J. Respir. Crit. Care Med. 157: 748–755
Lilis R, Miller A, Godbold J, Chan E, Selikoff IJ . 1991 Am. J. Ind. Med. 20: 1–15
Liu B, Fu DC, Miao Q, Wang HH, You BR . 1998 Biomed. Env. Sciences 11: 226–232
Lund L, Aust AE . 1992 Carcinogenesis 13: 637–642
Maples K, Johnson NF . 1992 Carcinogenesis 13: 2035–2039
Marczynski B, Czuppon AB, Marek W, Reichel G, Baur X . 1994 Human Exp. Toxicol. 13: 3–9
Marczynski B, Rozynek P, Kraus T, Schlosser S, Raithel HJ, Baur X . 2000 Mutat. Res. 468: 195–202
Menrad H, Noel L, Khorami J, Jouve JL, Dunnigan J . 1986 Environ. Res. 40: 84–91
Mollo F, Pira E, Piolatto G, Bellis D, Builo P, Andreozzi A, Bentempi S, Negri E . 1995 Int. J. Cancer 60: 289–293
Mossman B, Light W, Wei E . 1983 Annu. Rev. Pharmacol. Toxicol. 23: 595–675
Mossman B, Marsh JP, Shatos MA . 1986 Lab. Investig. 54: 204–212
Murata-Kamiya N, Tsutsui T, Fujino A, Kasai H, Kaji H . 1997 Int. Arch. Occup. Environ. Health 70: 321–326
Nejjari A, Fournier J, Pezerat H, Leanderson P . 1993 Br. J. Ind. Med. 50: 501–504
Nelson H, Wiencke JK, Gunn L, Wain JC, Christiani DC, Kelsey KT . 1998 Cancer Res. 58: 1804–1807
Nelson H, Christiani DC, Wiencke JK, Mark EJ, Wain JC, Kelsey KT . 1999 Cancer Res. 59: 4570–4573
Nuorva K, Makitaro R, Huhti E, Kamel D, Vahakangas K, Bloigu R, Soini Y, Paakko P . 1994 Am. J. Respir. Crit. Care Med. 150: 528–533
Okayasu R, Wu L, Hei TK . 1999 Br. J. Cancer 79: 1319–1324
Palekar L, Eyre JF, Most BM, Coffin DL . 1987 Carcinogenesis 8: 553–560
Park S, Aust AE . 1998 Cancer Res. 58: 1144–1148
Pylkkanen L, Wolff H, Stjernvall T, Tuominen P, Sioris T, Kargalainen A, Anttila S, Hasgafvel-Pursiainen K . 2002 Int. J. Oncol. 20: 285–290
Raffin E, Lynge E, Korsgaard B . 1993 Br. J. Ind. Med. 50: 85–89
Rom W, Livingston GK, Casey KT, Wood SD, Egger MJ, Chiu GL, Jerominski L . 1983 J. Natl. Cancer Inst. 70: 45–48
Rom W . 1998 Environmental and Occupational Medicine From W (ed) Philadelphia: Lippincott-Raven pp. 349–376
Rothman K . 1976 Am. J. Epidemiol. 103: 506–511
Russi M, Cone JE . 1994 Textbook of clinical occupational and environmental medicine Rosenstock L and Cullen MR (eds) Philadelphia: W.B. Saunders pp. 543–554
Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA . 2001 Cancer Res. 61: 2092–2096
Schapira R, Ghio AJ, Effros RM, Morrisey J, Dawson CA, Hacker AD . 1994 Am. J. Respir. Cell Mol. Biol. 10: 573–579
Sekhon H, Wright J, Churg A . 1995 Int. J. Exp. Path. 76: 411–418
Selikoff I, Hammond EC, Churg J . 1968 JAMA 204: 106–112
Sincock A, Seabright M . 1975 Nature 157: 56–58
Soutar C, Simon G, Turner-Warwick M . 1974 Br. J. Dis. Chest 68: 235–252
Takahashi K, Pan H, Kasai H, Hanaoka T, Feng Y, Liu N, Zhang S, Xu Z, Tsuda T, Yamato H, Higashi T, Okubo T . 1997 Int. J. Occup. Environ. Health 3: 111–119
Takeuchi T, Morimoto K . 1994 Carcinogenesis 15: 635–639
Talcott J, Antman KH . 1988 Curr. Probl. Cancer 12: 135–178
Vainio H, Boffetta P . 1994 Scand. J. Work Environ. 20: 235–242
Valerio F, De Ferrari M, Ottaggio L, Repetto E, Santi L . 1983 Mutat. Res. 122: 397–402
Wang X, Christiani DC, Wiencke JK, Fischbein M, Xu X, Cheng TJ, Mark E, Wain JC, Kelsey KT . 1995 Cancer Epidemiol. Biomark. Preven. 4: 543–548
Weiss W . 1988a Br. J. Ind. Med. 45: 544–547
Weiss W . 1988b J. Occ. Med. 30: 33–39
Weitzman S, Graceffa P . 1984 Arch. Biochem. Biophys. 228: 373–376
Whitwell F, Newhouse ML, Bennett DR . 1974 Br. J. Ind. Med. 31: 298–303
Wilt J, Parker JE, Banks DE . 1998 Occupational Lung Disease an International Perspecitve Banks D and Parker JE (eds) London: Chapman and Hall Medical pp. 119–138
Xu A, Wu L-J, Santella RM, Hei TK . 1999 Cancer Res. 59: 5922–5926
Yegles M, Saint-Etienne L, Renier A, Janson X, Jaurand MC . 1993 Am. J. Respir. Cell Mol. Biol. 9: 186–189
Zalma R, Bonneau L, Jaurand CM, Guignard J, Pezerat H . 1987 Can. J. Chem. 65: 2338–2341
Zochbauer-Muller S, Fong KM, Virmani AK, Gerardts J, Gazdar AF, Minna JD . 2001 Cancer Res. 61: 249–255
Acknowledgements
This study was supported by NIH grants P42ES5947, ES0002, P42ES07373, CA82354 and CA57494.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nelson, H., Kelsey, K. The molecular epidemiology of asbestos and tobacco in lung cancer. Oncogene 21, 7284–7288 (2002). https://doi.org/10.1038/sj.onc.1205804
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205804
Keywords
This article is cited by
-
The global burden of lung cancer: current status and future trends
Nature Reviews Clinical Oncology (2023)
-
Circulating microRNA-197-3p as a potential biomarker for asbestos exposure
Scientific Reports (2021)
-
Review of carcinogenicity of asbestos and proposal of approval standards of an occupational cancer caused by asbestos in Korea
Annals of Occupational and Environmental Medicine (2015)
-
p53 in head and neck cancer: Functional consequences and environmental implications of TP53mutations
Head & Neck Oncology (2010)